Chloroquine Alone or in Combination for Malaria in Children in Malawi
Information source: National Institute of Allergy and Infectious Diseases (NIAID)
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Plasmodium Falciparum Malaria
Intervention: Artesunate (Drug); Atovaquone-proguanil (Drug); Chloroquine (Drug); Azithromycin (Drug)
Phase: Phase 3
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Christopher Plowe, Phone: (410) 706-5328
Malaria is a sickness caused by a parasite that people can get from mosquito bites. If it is
not treated, malaria can make people very sick and even cause death, especially in children.
The purpose of this study is to find out if it is better to use chloroquine alone or in
combination with another drug to most effectively treat malaria. About 640 children with
malaria, aged 6 months to 5 years of age, from the Blantyre Malaria Project Research Clinic
at the Ndirande Health Center in Malawi will be in the study. They will be treated with
either chloroquine alone or a combination of chloroquine plus another medication
(azithromycin or artesunate or atovaquone-proguanil) every time they get malaria for a year.
Blood samples will be collected and tested at least every 4 weeks Participants will be
involved in the study for 1 year.
Official title: A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: The number of clinical malaria episodes.
To measure the prevalence of chloroquine resistant parasites, by treatment arm.
To assess the antimalarial drug efficacy, by treatment arm.
To assess the effect of each treatment arm on anemia.
To determine the chloroquine blood levels at which chloroquine sensitive and resistant parasites are able to cause infection.
Assess the spatial patterns and the environmental determinants of malaria infection.
Assess the effect of population movements on the risk of malaria infection.
To assess the safety of repeated use of the drugs in each of the study arms.
Combination therapy is becoming the mainstay of malaria treatment. In general, the goal of
combination therapy is to successfully treat resistant infections successfully and to prevent
the emergence and spread of resistance. The antimalarial combination therapies currently in
use were not designed based on optimal pairing of drugs to deter the development and spread
of parasite resistance to the individual partner drugs in settings of high malaria
transmission. Careful studies are needed to identify the pharmacokinetic and pharmacodynamic
properties of drug combinations that will deter resistance and prolong the useful therapeutic
life of the next generation of antimalarial drug combinations. Current in vivo methods for
measuring antimalarial drug efficacy in high-transmission areas use a 14 or 28-day follow-up
period, but a single-episode study misses several critical factors in assessing the efficacy
and impact of antimalarial treatment. When follow-up is extended beyond 28 days, more cases
of apparent resistance or treatment failure are found. Single-episode studies cannot assess
the impact of therapy on the incidence of malaria over time. These limitations of standard in
vivo studies have led the investigators to advocate longitudinal studies of drug efficacy. In
addition to measuring efficacy of individual treatments, longitudinal studies measure
sustained efficacy with repeated use of the same regimen over time, a scenario that more
accurately reflects the real-life use of anti-malarial medication. The primary outcome of
interest, the incidence of malaria episodes, as well as the secondary outcomes of anemia and
severe malaria, are all highly relevant to public health policy-makers, as they reflect not
only the burden of disease but also the utilization of health resources. Longitudinal studies
also permit assessment of how pharmacokinetic properties of drugs affect the incidence of
treatment episodes. This is a randomized, open-label, longitudinal drug efficacy trial
involving approximately 640 children, aged 6 months to 5 years, who are found to have
uncomplicated malaria at the Blantyre Malaria Project Research Clinic at the Ndirande Health
Centre in Blantyre, Malawi. After enrollment, participants will be randomized to one of four
treatment arms: chloroquine alone or chloroquine in combination with artesunate,
atovaquone-proguanil (Malarone® or AP), or azithromycin. The treatment outcome will be
assessed through a standard 28-day efficacy study. Participants subsequently will be
evaluated every four weeks and encouraged to return to the study clinic any time they are ill
during the course of one year. If a new episode of uncomplicated malaria is diagnosed, the
participant will receive the same therapy as assigned on enrollment. Polymerase chain
reaction-corrected 28-day efficacy will be evaluated for each treatment episode. The primary
study objective is to compare annual incidence of malaria clinical episodes. Secondary
objectives are to: assess anti-malarial drug efficacy at first administration, by treatment
arm; assess anti-malarial drug efficacy during subsequent episodes of malaria, by treatment
arm; measure prevalence of chloroquine resistant parasites during the trial, by treatment
arm; assess effect of each treatment arm on anemia at the end of study participation; assess
safety of these drugs with repeated use; determine the chloroquine blood levels at which
chloroquine sensitive and resistant parasites are able to cause infection; assess the effect
of population movements on the risk of malaria infection; and assess the spatial patterns and
the environmental determinants of malaria infection.
Minimum age: 6 Months.
Maximum age: 5 Years.
Patients aged >/= 6 months to 5 years presenting to Ndirande Health Centre with signs or
symptoms consistent with malaria including, but not limited to, one or more of the
- fever at the time of evaluation (axillary temperature >/= 37. 5 degrees C by digital
- report of fever within the last two days
- clinically profound anemia (conjunctival or palmar pallor)
- body aches
- abdominal pain
- decreased intake of food or fluids
- weakness Weight >/= 5kg Positive malaria smear for P. falciparum mono-infection with
parasite density 2,000-200,000/cubic millimeter Planning to remain in the study area
for 1 year Willingness to return for four-weekly routine visits as well as unscheduled
sick visits Parental/guardian consent for each participant
Signs of severe malaria: One or more of the following:
- hemoglobin = 5 g/dL
- respiratory distress
- recent seizures, coma or obtundation (Blantyre coma score < 5)
- inability to drink
- persistent vomiting Known allergy or history of adverse reaction to chloroquine,
artesunate, azithromycin or atovaquone-proguanil Chronic medication with any
antibiotic or anti-malarial medication Previous enrollment in this study Alanine
aminotransferase (ALT) more than 5x the upper limit of normal or creatinine greater
than 3x the upper limit of normal Evidence of chronic disease or physical stigmata of
severe malnutrition (i. e., loss of muscle mass or subcutaneous tissue, edema, or skin
or hair findings consistent with severe malnutrition)
Locations and Contacts
Christopher Plowe, Phone: (410) 706-5328
Blantyre Malaria Project, Blantyre, Malawi; Recruiting
Starting date: February 2007
Ending date: June 2009
Last updated: September 25, 2008